NGM-707

NGM-707 is a humanized monoclonal antibody that blocks ILT2 and ILT4 receptors. NGM-707 has the potential for the study of advanced and metastatic solid tumors[1].

Product Specifications

UNSPSC

12352203

Target

Transmembrane Glycoprotein

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[NGM-707]

References & Citations

[1]Judy S. Wang, et al. Abstract CT099: NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose escalation. Cancer Res (2024) 84 (7_Supplement) : CT099.